First major scientific study into rare inflammatory skin condition

July 25, 2012

Pyoderma gangrenosum (PG) is a rare, disfiguring and very painful skin condition which affects around 360 people each year in the UK.

The condition results in large painful which take many months to heal — often with scarring. The condition is also associated with a higher risk of death. The cause of PG is not known, although often have underlying health conditions such as inflammatory bowel disease and rheumatoid arthritis and it is still not clear how best to treat PG when it does develop.

Now, for the first time dermatology experts led by Hywel Williams, Professor of Dermato-Epidemiology at The University of Nottingham, are carrying out the largest study of its kind in the world into this painful skin condition. The hope is that the results will help change clinical practice.

The randomised controlled trial is funded by the National Institute for Health Research (NIHR) as part of a Programme Grant for Applied Research awarded to the CEBD which is being managed by the Nottingham Clinical Trials Unit. 

Professor Williams, Director of the Centre of Evidence Based Dermatology (CEBD), said: “Being told you have a rare and that very little evidence is out there to inform treatment because it is so uncommon is just not good enough in 2012. Many treatments have been tried, yet only one small clinical trial has ever been done on this condition. In order to guide doctors and patients about the best treatment, we have set up a national study together with University of Aberdeen to do a fair comparison of the two most commonly used treatments — oral steroids and ciclosporin.”

The search for answers

The STOP GAP Trial — Study of Treatments for Pyoderma Gangrenosum Patients — has already recruited just over a 175 patients — but more are needed before the study closes in October. It is hoped STOP GAP will provide some answers and inform clinicians on a “gold-standard” way of treating. 

There has only ever been one other randomised controlled trial into the condition. This was carried out in 2006 and had a sample size of 30 patients. STOP GAP is recruiting patients from across the UK, in around 40 hospitals, and is comparing two commonly used oral treatments — prednisolone (a steroid) and ciclosporin (an immuno-supressant). Both medicines help PG to heal to some extent but it is not clear which is best and which is safest.

For more information about the trial please go to: www.stopgaptrial.co.uk

Explore further: Patients with skin disease deserve better treatment

Related Stories

Patients with skin disease deserve better treatment

April 13, 2012
Better access to specialists, more relevant training for health professionals and the introduction of reliable data to manage services effectively — these are the recommendations of a major review carried out by experts ...

Clinical trial to test success of Cystic Fibrosis lung infection treatment

March 27, 2012
Experts from Bristol and Nottingham are leading a major new national study to investigate whether intravenous antibiotics are effective in killing a common germ that causes dangerous complications in cystic fibrosis (CF) ...

Study to test new tinnitus 'treatment'

March 20, 2012
A new clinical trial is to test whether a pocket-sized device that uses sound simulation to reboot faulty 'wiring' in the brain could cure people with the debilitating hearing disorder tinnitus.

Recommended for you

New approach to tracking how deadly 'superbugs' travel could slow their spread

November 22, 2017
Killer bacteria - ones that have out-evolved our best antibiotics—may not go away anytime soon. But a new approach to tracking their spread could eventually give us a fighting chance to keep their death toll down.

Research points to diagnostic test for top cause of liver transplant in kids

November 22, 2017
Biliary atresia is the most common cause of liver transplants for children in the United States. Now researchers report in Science Translational Medicine finding a strong biomarker candidate that could be used for earlier ...

Metabolites altered in chronic kidney disease

November 22, 2017
Chronic kidney disease (CKD) affects 1 in 7 people in the United States, according to the U.S. National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK). These individuals have a very high risk of cardiovascular ...

Rainfall can indicate that mosquito-borne epidemics will occur weeks later

November 22, 2017
A new study demonstrates that outbreaks of mosquito-borne viruses Zika and Chikungunya generally occur about three weeks after heavy rainfall.Researchers also found that Chikungunya will predominate over Zika when both circulate ...

Alcohol consumption and metabolic factors act together to increase the risk of severe liver disease

November 22, 2017
A new study provides insights into the interaction between alcohol consumption and metabolic factors in predicting severe liver disease in the general population. The findings, which are published in Hepatology, indicate ...

Gastric acid suppressant lansoprazole may target tuberculosis

November 21, 2017
A cheap and widely used drug, used to treat conditions such as heartburn, gastritis and ulcers, could work against the bacteria that cause tuberculosis (TB), according to new research from UCL and the London School of Hygiene ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.